Potent and selective α1A adrenoceptor partial agonists-Novel imidazole frameworks

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 11, 2009, Pages 3118-3121

  Whitlock, Gavin A ^a   Brennan, Paul E ^a   Roberts, Lee R ^a   Stobie, Alan ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

1A Adrenergic receptor; Partial agonist

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; GLYCOPROTEIN P; IMIDAZOLE; LIGAND; NITRILE; PARTIAL AGONIST; ADRENERGIC RECEPTOR ALPHA(1A); ADRENERGIC RECEPTOR ALPHA(1B); ADRENERGIC RECEPTOR ALPHA(1D); ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; IMIDAZOLE DERIVATIVE; RECEPTOR, ADRENERGIC, ALPHA 2A; RECEPTOR, ADRENERGIC, ALPHA-2A;

ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG SELECTIVITY; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; SOLUBILITY; ANIMAL; CELL LINE; CHEMISTRY; DOG; DRUG POTENTIATION; HUMAN; METABOLISM; SYNTHESIS;

ANIMALS; CELL LINE; DOGS; HUMANS; IMIDAZOLES; P-GLYCOPROTEIN; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 65149102695     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.03.162     Document Type: Article

References (12)

1. Hieble J.P., Bylund D.B., Clarke D.E., Eikenburg D.C., Langer S.Z., Lefzowitz R.J., Minneman K.P., and Ruffolo Jr. R.R. Pharmacol. Rev. 47 (1995) 267
2. Zhong H., and Minneman K.P. Eur. J. Pharmacol. 375 (1999) 261
3. Musselman D.M., Ford A.P.D.W., Gennevois D.J., Harbison M.L., Laurent A.L., Mokatrin A.S., Stoltz R.R., and Blue D.R. BJU Int. 93 (2004) 78
4. Whitlock G.A., Conlon K., McMurray G., Roberts L.R., Stobie A., and Thurlow R.J. Bioorg. Med. Chem. Lett. 18 (2008) 2930
5. Conlon, K.; Christy, C.; Whitlock, G. A.; Roberts, L. R.; Stobie, A.; Thurlow, R. J.; McMurray, G. J. Pharmacol. Exp. Ther., submitted for publication.
6. Roberts L.R., Bryans J., Conlon K., McMurray G., Stobie A., and Whitlock G.A. Bioorg. Med. Chem. Lett. 18 (2008) 6437
7. 1-receptor agonists, no N-alkylated imidazolines or imidazoles were described. Bishop M.J. Curr. Topics Med. Chem. 7 (2007) 135
8. 2 conditions were employed.
9. In silico molecular modeling calculated a 0.8 kcal/mol energy difference between axial and equatorial conformations of 5. This energy gap is well within the typical 5 kcal/mol difference observed for bound versus low energy conformations reported in the literature, see:. Perola E., and Charifson P.S. J. Med. Chem. 47 (2004) 2499
10. Wang Q., Rager J.D., Weinstein K., Kardos P.S., Dobson G.L., Li J., and Hidalgo I.J. Int. J. Pharm. 288 (2005) 349
11. max of 60% in our hands, which was in line with published data, see Blue, D. R.; Daniels, D. V.; Gever, J., R.; Jett, M. F.; O'Yang, C.; Tang, H. M.; Williams, T. J.; Ford, A. P. D. W. BJU Int. 2004, 93, 162. Ro 115-1240 was reported not to cause cardiovascular effects at the dose tested in the clinic, see Ref. 2.
12. Roberts L.R., Brennan P.E., Fish P.V., Storer R.I., and Whitlock G.A. Bioorg. Med. Chem. Lett. 19 (2009) 3113